Eradication of <scp>H</scp>elicobacter pylori Infection by the Probiotic Strains <scp>L</scp>actobacillus johnsonii <scp>MH</scp>‐68 and <scp>L</scp>. salivarius ssp. salicinius <scp>AP</scp>‐32

Hsieh, Ping-Cheng; Tsai, Yi‐Chun; Chen, Yi‐Chun; Teh, Su-Fen; Ou, Chung-Mou; King, V. An-Erl

doi:10.1111/j.1523-5378.2012.00992.x

Cited by 67 publications

(44 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Firstly, the bacteriocins generated by lactobacillus exert an inhibition on H. pylori directly, and some other probiotic bacterium including bifidobacterium and enterococcus may also suppress the viability of H. pylori by producing heat stable proteinaceous compounds (33). Secondly, it is concerning the secreted metabolites especially lactic acid produced by lactobacillus suppressing urease activity of H. pylori (34,35). Thirdly, the mechanism is that lactobacillus decreased the H. pylori load in the gastric mucosa through the stabilization of the mucosal barrier (36,37), to which the mucin secretion is the main approach, and it probably results from mucin gene allele mutation and expression (35,38,39).…”

Section: Discussionmentioning

confidence: 99%

“…Secondly, it is concerning the secreted metabolites especially lactic acid produced by lactobacillus suppressing urease activity of H. pylori (34,35). Thirdly, the mechanism is that lactobacillus decreased the H. pylori load in the gastric mucosa through the stabilization of the mucosal barrier (36,37), to which the mucin secretion is the main approach, and it probably results from mucin gene allele mutation and expression (35,38,39). Another mechanism is proposed to be the immunologic response which reduces inflammatory chemokine expression and lymphocyte infiltration (35,(40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lactobacillus -containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis

Zheng¹,

Lin²,

Mei³

2013

Rev. esp. enferm. dig.

103

View full text Add to dashboard Cite

Background: Helicobacter pylori infection is recognized as a major contributory factor to many diseases, but recommended eradication therapies demonstrated unsatisfactory eradication rates. Currently, some studies suggested that lactobacillus species have an inhibitory action on Helicobacter pylori both in vitro and in vivo.Objective: this meta-analysis broadly examined the efficacy of eradication regimens supplemented with lactobacillus-containing probiotic on eradication rates and side effects.Methods: eligible articles were identified by comprehensive searches. Statistical analysis was performed with Review Manager 5.2. Outcomes were finally evaluated according to GRADE system.Results: nine randomized controlled trials of high-quality met eligible criteria. Risk ratio of eradication was available for 1,163 patients. Lactobacillus-containing probiotics significantly increased the eradication rate compared with the control group based upon intention-to-treat analysis [RR = 1.14; 95 %CI (1.06-1.22); number needed to treat (NNT) = 10] by the fixed effect model without significant publication bias, but no significant reduction associated with overall side effects was observed [RR = 0.88;]. In the subgroup analysis, eradication rates raised significantly by 17 % in lactobacillus administrated alone group [RR = 1.25; 95 %CI (1.13-1.37); NNT = 6]. In multistrain probiotics group, eradication rates enhanced only 2.8 % [RR = 1.04; 95 %CI (0.94-1.14)]. It also showed that lactobacillus-containing probiotics improved the eradication rates, respectively, both in adults [RR = 1.12; Conclusions: Lactobacillus-containing probiotic as an adjunct is effective to eradication therapy, while side effects caused by eradication treatment may not decrease. Furthermore, lactobacillus administrated alone will distinctly benefit eradication therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Lactobacillus -containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis

Zheng¹,

Lin²,

Mei³

2013

Rev. esp. enferm. dig.

103

View full text Add to dashboard Cite

show abstract

“…The reason is likely to be that L. acidophilus itself may also be able to improve the degree of inflammation caused by H. pylori infection. Possible mechanisms for this are as follows: (i) L. acidophilus may adhere to and colonize the gastric mucosa in ad- (46)(47)(48). Compared with traditional vaccine vectors, LAB have several advantages, including being safer and nontoxic, being able to adhere to and colonize the respiratory tract, digestive tract, and other mucosal epithelial cell layers, and functioning to express and to secrete heterologous proteins and to induce strong mucosal immune responses (29,49).…”

Section: Discussionmentioning

confidence: 99%

Oral Immunization with Recombinant Lactobacillus acidophilus Expressing the Adhesin Hp0410 of Helicobacter pylori Induces Mucosal and Systemic Immune Responses

Fan¹,

Wu²,

Fang³

et al. 2013

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Helicobacter pylori infection is relatively common worldwide and is closely related to gastric mucosa-associated lymphoid tissue (MALT) lymphoma, chronic gastritis, and stomach ulcers. Therefore, a safe and effective method for preventing H. pylori infection is urgently needed. Given that developing an effective vaccine against H. pylori is one of the best alternatives, H. pylori adhesin Hp0410 was expressed in the food-grade bacterium Lactobacillus acidophilus. The recombinant live bacterial vaccine was then used to orally vaccinate mice, and the immunoprotective effects of Hp0410-producing strains were investigated. H. pylori colonization in the stomach of mice immunized with the recombinant L. acidophilus was significantly reduced, in comparison with that in control groups. Furthermore, mucosal secretory IgA antibodies were elicited in the mucosal tissue of mice immunized with the recombinant bacteria, and specific anti-Hp0410 IgG responses were also detected in mouse serum. There was a significant increase in the level of protection against gastric Helicobacter infection following a challenge with H. pylori Sydney strain 1 (SS1). Our results collectively indicate that adhesin Hp0410 is a promising candidate vaccine antigen, and recombinant L. acidophilus expressing Hp0410 is likely to constitute an effective, low-cost, live bacterial vaccine against H. pylori.

show abstract

“…Probiotics would be an excellent tool in controlling bacterial overgrowth and reduce these effects [31-34]. There is also evidence that probiotics may also inhibit the growth of H. pylori , stimulate an immunological response and reduce the inflammatory effects of infection by bacteria [35-37] increasing the rate of H. pylori eradication [38-40]. …”

Section: Introductionmentioning

confidence: 99%

Association of a probiotic to a Helicobacter pylorieradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study

et al. 2013

View full text Add to dashboard Cite

BackgroundThe treatment for the eradication of Helicobacter pylori (H. pylori) is complex; full effectiveness is rarely achieved and it has many adverse effects. In developing countries, increased resistance to antibiotics and its cost make eradication more difficult. Probiotics can reduce adverse effects and improve the infection treatment efficacy.If the first-line therapy fails a second-line treatment using tetracycline, furazolidone and proton-pump inhibitors has been effective and low cost in Brazil; however it implies in a lot of adverse effects. The aim of this study was to minimize the adverse effects and increase the eradication rate applying the association of a probiotic compound to second-line therapy regimen.MethodsPatients with peptic ulcer or functional dyspepsia infected by H. pylori were randomized to treatment with the furazolidone, tetracycline and lansoprazole regimen, twice a day for 7 days. In a double-blind study, patients received placebo or a probiotic compound (Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum and Streptococcus faecium) in capsules, twice a day for 30 days. A symptom questionnaire was administered in day zero, after completion of antibiotic therapy, after the probiotic use and eight weeks after the end of the treatment. Upper digestive endoscopy, histological assessment, rapid urease test and breath test were performed before and eight weeks after eradication treatment.ResultsOne hundred and seven patients were enrolled: 21 men with active probiotic and 19 with placebo plus 34 women with active probiotic and 33 with placebo comprising a total of 55 patients with active probiotic and 52 with placebo. Fifty-one patients had peptic ulcer and 56 were diagnosed as functional dyspepsia. The per-protocol eradication rate with active probiotic was 89.8% and with placebo, 85.1% (p = 0.49); per intention to treat, 81.8% and 79.6%, respectively (p = 0.53). The rate of adverse effects at 7 days with the active probiotic was 59.3% and 71.2% with placebo (p = 0.20). At 30 days, it was 44.9% and 60.4%, respectively (p = 0.08).ConclusionsThe use of this probiotic compound compared to placebo in the proposed regimen in Brazilian patients with peptic ulcer or functional dyspepsia showed no significant difference in efficacy or adverse effects.Trial registrationCurrent Controlled Trials ISRCTN04714018

show abstract

Eradication of Helicobacter pylori Infection by the Probiotic Strains Lactobacillus johnsonii MH‐68 and L. salivarius ssp. salicinius AP‐32

Abstract: Lactobacillus johnsonii MH-68 and L. salivarius subsp. salicinius AP-32 effectively suppress H. pylori viability, and when used as probiotics, they may help decrease the occurrence of gastritis, and even reduce the risk of H. pylori infection.

Cited by 67 publications

References 42 publications

Lactobacillus -containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis

Lactobacillus -containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis

Oral Immunization with Recombinant Lactobacillus acidophilus Expressing the Adhesin Hp0410 of Helicobacter pylori Induces Mucosal and Systemic Immune Responses

Association of a probiotic to a Helicobacter pylorieradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study

Contact Info

Product

Resources

About